As the mRNA field continues to surge with the first non-COVID approval from Moderna, the 3rd mRNA Process Development & Manufacturing Summit returned to Boston this September - poised to address the industry's most prevalent bottlenecks of speed, cost of production, and limited flexibility. This was your chance to expedite your mRNA drugs to the clinic and beyond with efficient production, regardless of scale.

40+ expert speakers from the likes of Moderna, Pfizer, Sanofi and BioNTech took center stage to help you optimize IVT reactions, implement high throughput process development, scale up mRNA synthesis and purification, optimize drug product formulation and much more.

We dived into two content tracks dedicated to Research Scale and IND Enabling & Clinical Scale mRNA production with sessions spanning the mRNA process chain from pDNA synthesis to mRNA drug product formulation, designed to help your team accelerate workflows at eachstage, and across all scales of mRNA production.

We networked with 150+ VPs, Directors and Heads of Process Development, In Vitro Transcription, CMC, MSAT and more as we sought to set manufacturing frameworks, which enabled us to support your R&D and analytical teams to supercharge safe and effective mRNA drugs from research into the clinic and beyond.